For Healthcare Professionals

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

clipboard-pencil

About the study

The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Histological confirmation of diagnosis at last relapse
  2. Adequate organ function
  3. Adequate vascular access for leukapheresis procedure

EXCLUSION CRITERIA

  1. Prior history of malignancies, other than aggressive relapsed/refractory Non-Hodgkin Lymphoma, unless the participant has been in remission for ≥ 2 years with the exception of non-invasive malignancies
  2. Received previous CD19-targeted therapy
  3. Progressive vascular tumor invasion, thrombosis, or embolism Other protocol-defined inclusion/exclusion criteria apply
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-888-260-1599Email iconEmail Study Center

Study’s details


Contition

Lymphoma, Non-Hodgkin

Age

18+

Phase

Phase 2

Participants needed

112

Est. Completion Date

Dec 2023

Treatment type

Interventional


Sponsor

Celgene

ClinicalTrials.gov identifier

NCT03484702

Study number

JCAR017-BCM-001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.